MedTrace Logo

Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia

NCT07335965 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-01-13

No results posted yet for this study

Summary

Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species.

A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.

Conditions

  • Borrelia Recurrentis Infection

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-19
Primary Completion
2026-10-31
Completion
2026-10-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07335965 on ClinicalTrials.gov